Table 2. G8 scores and patient characteristics (n = 101).
| Total | Normal G8 scores | Impaired G8 scores | p value | ||
|---|---|---|---|---|---|
| n = 101 | n = 18 | n = 83 | |||
| Age | 80> | 56 | 14 (25%) | 42 (75%) | 0.04* |
| ≥80 | 45 | 4 (9%) | 41 (91%) | ||
| Sex | Male | 81 | 17 (21%) | 64 (79%) | 0.11 |
| Female | 20 | 1 (5%) | 19 (95%) | ||
| Histology | NSCLC | 82 | 14 (17%) | 68 (83%) | 0.74 |
| SCLC | 19 | 4 (21%) | 15 (79%) | ||
| ECOG PS | 0–1 | 58 | 18 (31%) | 40 (69%) | <0.0001* |
| ≥2 | 43 | 0 (0%) | 43 (100%) | ||
| Stage | I–III | 40 | 6 (15%) | 34 (85%) | 0.61 |
| IV | 61 | 12 (20%) | 49 (80%) | ||
| Treatment received | Non-chemotherapy | 25 | 0 (0%) | 25 (100%) | 0.11 |
| Chemotherapy | 76 | 18 (24%) | 58 (76%) |
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; PS, Performance status.
*Statistically significant (p < 0.05)